Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Indolent Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00406809
What this trial is testing

ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Chronic Lymphoid LeukemiaLymphoid MalignanciesNon-Hodgkin's Lymphoma+3 more
AbbVie (prior sponsor, Abbott) 81
Early research (Phase 1)Study completedNCT00068315
What this trial is testing

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHematopoietic/Lymphoid CancerNodal Marginal Zone B-cell Lymphoma+9 more
National Cancer Institute (NCI) 18
Not applicableEnded earlyNCT00005786
What this trial is testing

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaProlymphocytic Leukemia+8 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Looking for participantsNCT06530550
What this trial is testing

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China 51
Testing effectiveness (Phase 2)WithdrawnNCT07030699
What this trial is testing

Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01882803
What this trial is testing

Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Indolent Non-Hodgkin Lymphoma
SecuraBio 129
Testing effectiveness (Phase 2)Study completedNCT00220285
What this trial is testing

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, B-CellLymphoma, Low-Grade
Bayer 45
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Large-scale testing (Phase 3)Study completedNCT01059630
What this trial is testing

Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Who this might be right for
Non-Hodgkin's Lymphoma
Genentech, Inc. 413
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Testing effectiveness (Phase 2)Study completedNCT00069758
What this trial is testing

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Cephalon 72
Large-scale testing (Phase 3)Study completedNCT01461928
What this trial is testing

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 692
Early research (Phase 1)Study completedNCT00058227
What this trial is testing

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular Lymphoma+40 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Early research (Phase 1)Study completedNCT02242045
What this trial is testing

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaFollicular Lymphoma+3 more
Gilead Sciences 6
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Testing effectiveness (Phase 2)Active Not RecruitingNCT05025800
What this trial is testing

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+17 more
M.D. Anderson Cancer Center 47
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Next Page
24